VISTAGEN THERAPEUTICS, INC.

Analyst Reco. Vistagen Therapeutics, Inc.

Equities

VTGN

US92840H4002

Market Closed - Nasdaq Other stock markets 04:00:03 2024-05-31 pm EDT			5-day change	1st Jan Change
3.865 ^USD	-0.64%		-5.27%	-24.81%

May. 23	Vistagen Therapeutics, Inc. to Present At the 2024 American Society of Clinical Psychopharmacology Conference	CI
Apr. 25	Vistagen Announces Positive Results from Phase 2A Pilot Study of Ph15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue	CI

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Jefferies Upgrades VistaGen Therapeutics to Buy From Hold, Raises Price Target to $15 From $6	Dec. 07	MT
Stifel Starts VistaGen Therapeutics With Buy Rating, $12 Price Target	Nov. 14	MT
Maxim Cuts Price Target on VistaGen Therapeutics to $12 From $30, Maintains Buy Rating	23-10-17	MT
Rate hike fears return with a vengeance	23-10-17
Maxim Downgrades VistaGen Therapeutics to Hold From Buy	22-07-26	MT
Jefferies Downgrades VistaGen Therapeutics to Hold from Buy, Adjusts Price Target to $0.20 from $8	22-07-22	MT
William Blair Downgrades VistaGen Therapeutics to Market Perform From Outperform	22-07-22	MT
VISTAGEN THERAPEUTICS : Baird Starts VistaGen Therapeutics at Outperform With $9 Price Target	21-05-20	MT
VISTAGEN THERAPEUTICS : Jefferies Starts VistaGen Therapeutics at Buy with $6 Price Target	21-02-18	MT
VISTAGEN THERAPEUTICS : William Blair Upgrades VistaGen Therapeutics to Outperform From Market Perform	21-01-04	MT
VISTAGEN THERAPEUTICS : Maxim Adjusts Price Target on VistaGen Therapeutics to $5 From $3, Reiterates Buy Rating	20-12-22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer